USW1 NURS 6521 Courseschedule

Course Schedule
NURS 6521: Advanced Pharmacology
This Course Schedule outlines the assignments and due dates for the course. For full
assignment details and directions, refer to the corresponding area in the course.
Module 1: Foundational Concepts of Advanced Pharmacology

Week 1 Basic Pharmacotherapeutic Concepts/Ethical and Legal Aspects
of Prescribing
Resources Readings
• Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s

pharmacotherapeutics for advanced practice nurses and
physician assistants (2nd ed.) St. Louis, MO: Elsevier.
o Chapter 1, “Prescriptive Authority” (pp. 1–3)
o Chapter 2, “Rational Drug Selection and Prescription
Writing” (pp. 4–7)
o Chapter 3, “Promoting Positive Outcomes of Drug
Therapy” (pp. 8–12)
o Chapter 4, “Pharmacokinetics, Pharmacodynamics, and
Drug Interactions” (pp. 13–33)
o Chapter 5, “Adverse Drug Reactions and Medication
Errors” (pp. 34–42)
o Chapter 6, “Individual Variation in Drug Response” (pp.
43–45)
• American Geriatrics Society 2019 Beers Criteria Update

Expert Panel. (2019). American Geriatrics Society 2019
updated AGS Beers criteria for potentially inappropriate
medication use in older adults. Journal of the American
Geriatrics Society, 67(4), 674–694. doi:10.1111/jgs.15767
• Drug Enforcement Administration. (n.d.-a). Code of federal

regulations. Retrieved February 1, 2019, from
https://www.deadiversion.usdoj.gov/21cfr/cfr/1300/1300_01.ht
m
© 2021 Walden University, LLC Page 1 of 18

of Prescribing
• Drug Enforcement Administration. (n.d.-b). Mid-level
practitioners authorization by state. Retrieved May 13, 2019
from
http://www.deadiversion.usdoj.gov/drugreg/practioners/index.h
tml
• Drug Enforcement Administration. (2006). Practitioner’s

manual. Retrieved from
http://www.legalsideofpain.com/uploads/pract_manual090506.
pdf
• Drug Enforcement Administration. (n.d.-c). Registration.

Retrieved February 1, 2019, from
https://www.deadiversion.usdoj.gov/drugreg/index.html
• Fowler, M. D. M., & American Nurses Association. (2015).

Guide to the Code of Ethics for Nurses with Interpretive
Statements: Development, Interpretation, and Application (2nd
ed.). Silver Spring, Maryland: American Nurses Association.
• Institute for Safe Medication Practices. (2017). List of error-

prone abbreviations, symbols, and dose designations.
Retrieved from https://www.ismp.org/recommendations/error-
prone-abbreviations-list
• Ladd, E., & Hoyt, A. (2016). Shedding light on nurse

practitioner prescribing. The Journal for Nurse Practitioners,
12(3), 166–173. doi:10.1016/j.nurpra.2015.09.17
• Sabatino, J. A., Pruchnicki, M. C., Sevin, A. M., Barker, E.,

Green, C. G., & Porter, K. (2017). Improving prescribing
practices: A pharmacist‐led educational intervention for nurse
practitioner students. Journal of the American Association of
Nurse Practitioners, 29(5), 248–254. doi:10.1002/2327-
6924.12446
Media
• Laureate Education (Producer). (2012). Introduction to

advanced pharmacology [Video file]. Baltimore, MD: Author.

of Prescribing
• Nature Video. (2016). The evolution of oral anticoagulants
[Video]. https://www.youtube.com/watch?v=Gp-ucDRiaUA
• Speed Pharmacology. (2015). Pharmacology –

Pharmocokinetics (Made Easy) [Video].
https://www.youtube.com/watch?v=NKV5iaUVBUI&t=16s
• Speed Pharmacology. (2017). Pharmacology – Diuretics

(Made Easy) [Video].
https://www.youtube.com/watch?v=9OBvNpnS0h4&t=664s
• Speed Pharmacology. (2017). Pharmacology – Antiarrhythmic

Drugs (Made easy) [Video].
https://www.youtube.com/watch?v=9xSqezCMHnw&t=1205s
• Speed Pharmacology. (2016). Pharmacology – Adrenergic

receptors & agonists (MADE EASY) [Video].
https://www.youtube.com/watch?v=KtmV-yMDYPI&t=372s
• Speed Pharmacology. (2017). Drugs for Hyperlipidemia (Made

Easy) [Video]. https://www.youtube.com/watch?v=Of1Aewx-
zRM&t=24s
Discussion Pharmacokinetics and Pharmacodynamics
By Day 3 of Week 1
Post a description of the case you were assigned. Then, describe

factors that might have influenced pharmacokinetic and
pharmacodynamic processes of the patient from the case you were
assigned. Finally, explain details of the personalized plan of care that
you would develop based on influencing factors and patient history in
your case.
By Day 6 of Week 1
Read a selection of your colleagues’ responses and respond to at

least two of your colleagues on two different days by suggesting
additional patient factors that might have interfered with the
pharmacokinetic and pharmacodynamic processes of the patients in
their case studies. In addition, suggest how the personalized plan of
care might change if the age of the patient were different and/or if the

of Prescribing
patient had a comorbid condition, such as renal failure, heart failure,
or liver failure.
Assignment 1 Course Acknowledgements
Assignment 2 Ethical and Legal Implications of Prescribing Drugs
By Day 7 of Week 1
Write a 2- to 3-page paper that addresses the following:
• Explain the ethical and legal implications of the scenario you

selected on all stakeholders involved, such as the prescriber,
pharmacist, patient, and patient’s family.
• Describe strategies to address disclosure and nondisclosure
as identified in the scenario you selected. Be sure to reference
laws specific to your state.
• Explain two strategies that you, as an advanced practice
nurse, would use to guide your decision making in this
scenario, including whether you would disclose your error. Be
sure to justify your explanation.
• Explain the process of writing prescriptions, including
strategies to minimize medication errors.
Module 2: Cardiovascular and Respiratory Systems

Week 2 Cardiovascular System
Resources Readings

o Chapter 33, “Review of Hemodynamics” (pp. 285–289)
o Chapter 37, “Diuretics” (pp. 290–296)
o Chapter 38, “Drugs Acting on the Renin-Angiotensin-
Aldosterone System” (pp. 297–307)
o Chapter 39, “Calcium Channel Blockers” (pp. 308–312)
o Chapter 40, “Vasodilators” (pp. 313–317)
o Chapter 41, “Drugs for Hypertension” (pp. 316–324)
o Chapter 42, “Drugs for Heart Failure” (pp. 325–336)
o Chapter 43, “Antidysrhythmic Drugs” (pp. 337–348)

o Chapter 44, “Prophylaxis of Atherosclerotic
Cardiovascular Disease: Drugs That Help Normalize
Cholesterol and Triglyceride Levels” (pp. 349–363)
o Chapter 45, “Drugs for Angina Pectoris” (pp. 364–371)
o Chapter 46, “Anticoagulant and Antiplatelet Drugs” (pp.
372–388)
Media
• Laureate Education (Producer). (2009). Cardiovascular

disorders [Video file]. Baltimore, MD: Author.
• Walden University. (n.d.). Instructor feedback.

https://mym.cdn.laureate-
media.com/2dett4d/Walden/WWOW/1001/pulse_check/instruc
tor_feedback/index.html#/
Assignment Pharmacotherapy for Cardiovascular Disorders
By Day 7 of Week 2
Write a 2- to 3-page paper that addresses the following:
• Explain how the factor you selected might influence the

pharmacokinetic and pharmacodynamic processes in the
patient from the case study you were assigned.
• Describe how changes in the processes might impact the
patient’s recommended drug therapy. Be specific and provide
examples.
• Explain how you might improve the patient’s drug therapy plan
and explain why you would make these recommended
improvements.
Week 3 Respiratory System
Resources Readings

o Chapter 62, “Drugs for Asthma and Chronic Obstructive
Pulmonary Disease” (pp. 557–579)
o Chapter 63, “Drugs for Allergic Rhinitis, Cough, and
Colds” (pp. 580–588)

• Document: APA Presentation Template (PowerPoint

presentation)
Media
• Speed Pharmacology. (2020). Drugs for asthma and COPD

(Made Easy) [Video]. https://www.youtube.com/watch?v=-
DVZ9pl0rGY
•Speed Pharmacology. (2017). Antihistamines (Made Easy)

[Video].
https://www.youtube.com/watch?v=D5PHANcdA_E&t=25s
Assignment Asthma and Stepwise Management
By Day 7 of Week 3
Create a 5- to 6-slide PowerPoint presentation that can be used in a

staff development meeting on presenting different approaches for
implementing the stepwise approach for asthma treatment. Be sure to
address the following:
• Describe long-term control and quick relief treatment options

for the asthma patient from your practice as well as the impact
these drugs might have on your patient.
• Explain the stepwise approach to asthma treatment and
management for your patient.
• Explain how stepwise management assists health care
providers and patients in gaining and maintaining control of the
disease. Be specific.
Module 3: Gastrointestinal and Hepatobiliary Systems

Week 4 Gastrointestinal and Hepatobiliary Disorders
Resources Readings

o Chapter 64, “Drugs for Peptic Ulcer Disease” (pp. 589–
597)
o Chapter 65, “Laxatives” (pp. 598–604)

Module 3: Gastrointestinal and Hepatobiliary Systems
Week 4 Gastrointestinal and Hepatobiliary Disorders
o Chapter 66, “Other Gastrointestinal Drugs” (pp. 605–

616)
o Chapter 80, “Antiviral Agents I: Drugs for Non-HIV Viral
Infections” (pp. 723–743)
• Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi,

K., Rinella, M., . . . Sanya, A. J. (2018). The diagnosis and
management of nonalcoholic fatty liver disease: Practice
guidance from the American Association for the Study of Liver
Diseases. Hepatology, 67(1), 328–357. Retrieved from
https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.2
9367
Assignment Pharmacotherapy for Gastrointestinal and Hepatobiliary

Disorders
By Day 7 of Week 4
Write a 1-page paper that addresses the following:
• Explain your diagnosis for the patient, including your rationale

for the diagnosis.
• Describe an appropriate drug therapy plan based on the
patient’s history, diagnosis, and drugs currently prescribed.
• Justify why you would recommend this drug therapy plan for
this patient. Be specific and provide examples.
Module 4: Endocrine System

Week 5 Endocrine System Disorders and the Treatment of Diabetes
Resources Readings

o Chapter 48, “Drugs for Diabetes Mellitus” (pp. 397–415)
o Chapter 49, “Drugs for Thyroid Disorders” (pp. 416–
424)

Module 4: Endocrine System
Week 5 Endocrine System Disorders and the Treatment of Diabetes
• American Diabetes Association. (2018). Pharmacologic

approaches to glycemic treatment: Standards of medical care
in diabetes—2018. Diabetes Care, 41(Supplement 1), S73–
S85. Retrieved from
http://care.diabetesjournals.org/content/41/supplement_1/s73.f
ull-text.pdf
• Document: Mid-Term Summary & Study Guide (PDF)
Media
• Speed Pharmacology. (2017). Drugs for Diabetes (Made Easy)

[Video].
https://www.youtube.com/watch?v=LWDQyaKVols&t=79s
Discussion Diabetes and Drug Treatments
By Day 3 of Week 5
Post a brief explanation of the differences between the types of

diabetes, including type 1, type 2, gestational, and juvenile diabetes.
Describe one type of drug used to treat the type of diabetes you
selected, including proper preparation and administration of this drug.
Be sure to include dietary considerations related to treatment. Then,
explain the short-term and long-term impact of this type of diabetes
on patients. including effects of drug treatments. Be specific and
provide examples.
By Day 6 of Week 5

least two of your colleagues on two different days who selected a
different type of diabetes than you did. Provide recommendations for
alternative drug treatments and patient education strategies for
treatment and management.
Module 5: Neurologic and Musculoskeletal Systems and Opioids

Week 6 Neurologic and Musculoskeletal Disorders and Opioids
Resources Readings

o Chapter 11, “Basic Principles of Neuropharmacology”
(pp. 67–71)
o Chapter 12, “Physiology of the Peripheral Nervous
System” (pp. 72–81)
o Chapter 12, “Muscarinic Agonists and Cholinesterase
Inhibitors” (pp. 82–89)
o Chapter 14, “Muscarinic Antagonists” (pp. 90-98)
o Chapter 15, “Adrenergic Agonists” (pp. 99–107)
o Chapter 16, “Adrenergic Antagonists” (pp. 108–119)
o Chapter 17, “Indirect-Acting Antiadrenergic Agents” (pp.
120–124)
o Chapter 18, “Introduction to Central Nervous System
Pharmacology” (pp. 125–126)
o Chapter 19, “Drugs for Parkinson Disease” (pp. 127–
142)
o Chapter 20, “Drugs for Alzheimer Disease” (pp. 159–
166)
o Chapter 21, “Drugs for Seizure Disorders” (pp. 150–
170)
o Chapter 22, “Drugs for Muscle Spasm and Spasticity”
(pp. 171–178)
o Chapter 24, “Opioid Analgesics, Opioid Antagonists,
and Nonopioid Centrally Acting Analgesics” (pp. 183–
194)
o Chapter 59, “Drug Therapy of Rheumatoid Arthritis” (pp.
513–527)
o Chapter 60, “Drug Therapy of Gout” (pp. 528–536)
o Chapter 61, “Drugs Affecting Calcium Levels and Bone
Mineralization” (pp. 537–556)
• American Academy of Family Physicians. (2019). Dementia.

Retrieved from
http://www.aafp.org/afp/topicModules/viewTopicModule.htm?to
picModuleId=5
• Linn, B. S., Mahvan, T., Smith, B. E. Y., Oung, A. B.,

Aschenbrenner, H., & Berg, J. M. (2020). Tips and tools for
safe opioid prescribing: This review--with tables summarizing
opioid options, dosing considerations, and recommendations
for tapering--will help you provide rigorous Tx for noncancer
pain while ensuring patient safety. Journal of Family Practice,
69(6), 280–292.

• Document: Mid-Term Summary & Study Guide (PDF)
Media
• Laureate Education (Producer). (2019b). Alzheimer’s disease

[Interactive media file]. Baltimore, MD: Author.
• Laureate Education (Producer). (2019e). Complex regional

pain disorder [Interactive media file]. Baltimore, MD: Author.
• Laureate Education (Producer). (2019f). Disorders of the

nervous system [Video file]. Baltimore, MD: Author.
• Speed Pharmacology. (2019). Drugs for Parkinson’s Disease

(Made Easy) [Video].
https://www.youtube.com/watch?v=Z84iypHdftQ&t=13s
• Speed Pharmacology. (2019). Pharmacology- Drugs for

Alzheimer's Disease (Made Easy) [Video].
https://www.youtube.com/watch?v=euzRPrvrwj0&t=31s
Assignment Decision Tree for Neurological and Musculoskeletal Disorders
Note: This Assignment isn’t due until the end of Week 8.
By Day 7 of Week 8
Write a 1- to 2-page summary paper that addresses the following:
• Briefly summarize the patient case study you were assigned,

including each of the three decisions you took for the patient
presented.
• Based on the decisions you recommended for the patient case
study, explain whether you believe the decisions provided
were supported by the evidence-based literature. Be specific
and provide examples. Be sure to support your response with
evidence and references from outside resources.
• What were you hoping to achieve with the decisions you
recommended for the patient case study you were assigned?
Support your response with evidence and references from
outside resources.
• Explain any difference between what you expected to achieve
with each of the decisions and the results of the decision in the

exercise. Describe whether they were different. Be specific
and provide examples.
Week 7 Midterm Exam
Project Midterm Exam
By Day 7 of Week 7
The Midterm Exam is due. You have 120 minutes to complete the
exam. You may only attempt this exam once.
Module 6: Psychological Disorders

Week 8 Pharmacology for Psychological Disorders
Resources Readings

o Chapter 26, “Antipsychotic Agents and Their Use in
Schizophrenia” (pp. 203–213)
o Chapter 27, “Antidepressants” (pp. 214–226)
o Chapter 28, “Drugs for Bipolar Disorder” (pp. 228–233)
o Chapter 29, “Sedative-Hypnotic Drugs” (pp. 234–242)
o Chapter 30, “Management of Anxiety Disorders” (pp.
243–247)
o Chapter 31, “Central Nervous System Stimulants and
Attention-Deficit/Hyperactivity Disorder” (pp. 248–254)
Media
• Laureate Education (Producer). (2019a). Adult geriatric

depression [Interactive media file]. Baltimore, MD: Author.
• Laureate Education (Producer). (2019c). Attention deficit

hyperactivity disorder [Interactive media file]. Baltimore, MD:
Author.
• Laureate Education (Producer). (2019d). Bipolar therapy

[Interactive media file]. Baltimore, MD: Author.

Module 6: Psychological Disorders
Week 8 Pharmacology for Psychological Disorders
• Laureate Education (Producer). (2019g). Generalized anxiety

disorder [Interactive media file]. Baltimore, MD: Author.
• Speed Pharmacology. (2016). Pharmacology -

Antidepressants - SSRIs, SNRIs, TCAs, MAOIs, Lithium (Made
Easy) [Video].
https://www.youtube.com/watch?v=T25jvLC6X0w&t=3s
• Speed Pharmacology. (2018). Pharmacology -

Benzodiazepines, Barbiturates, Hypnotics (Made Easy)
[Video].
https://www.youtube.com/watch?v=4ZHudeMho8g&t=24s
Discussion Comparing and Contrasting Pharmacologic Options for the

Treatment of Generalized Anxiety Disorder
By Day 3 of Week 8
Post a discussion of pharmacokinetics and pharmacodynamics

related to anxiolytic medications used to treat GAD. In your
discussion, utilizing the discussion highlights, compare and contrast
different treatment options that can be used.
By Day 6 of Week 8

least two of your colleagues on two different days by suggesting
additional factors that might have interfered with the pharmacokinetic
and pharmacodynamic processes of the patients diagnosed with
GAD. In addition, suggest different treatment options you would
suggest to treat a patient with the topic of discussion.
Assignment Decision Tree for Neurological and Musculoskeletal
Submit your completed Assignment by Day 7 of Week 8.
Module 7: Women’s and Men’s Health, Infections, and Hematologic Systems

Week 9 Women’s and Men’s Health/Infections and Hematologic
Systems, Part I
Resources Readings


364–371)
o Chapter 47, “Drugs for Deficiency Anemias” (pp. 389–396)
o Chapter 50, “Estrogens and Progestins: Basic
Pharmacology and Noncontraceptive Applications” (pp.
425–436)
o Chapter 51, “Birth Control” (pp. 437–446)
o Chapter 52, “Androgens” (pp. 447–453)
o Chapter 53, “Male Sexual Dysfunction and Benign Prostatic
Hyperplasia” (pp. 454–466)
o Chapter 70, “Basic Principles of Antimicrobial Therapy” (pp.
651–661)
o Chapter 71, “Drugs That Weaken the Bacterial Cell Wall I:
Penicillins” (pp. 662–668)
o Chapter 75, “Sulfonamides Antibiotics and Trimethoprim”
(pp. 688–694)
o Chapter 76, “Drug Therapy of Urinary Tract Infections” (pp.
695–699)
o Chapter 78, “Miscellaneous Antibacterial Drugs” (pp. 711–
714)
o Chapter 79, “Antifungal Agents” (pp. 715–722)
o Chapter 82, “Drug Therapy of Sexually Transmitted
Diseases” (pp. 763–770)
• Lunenfeld, B., Mskhalaya, G., Zitzmann, M., Arver, S.,

Kalinchenko, S., Tishova, Y., & Morgentaler, A. (2015).
Recommendations on the diagnosis, treatment and monitoring
of hypogonadism in men. Aging Male, 18(1), 5–15.
doi:10.3109/13685538.2015.1004049
• Montaner, J. S. G., Lima, V. D., Harrigan, P. R., Lourenço, L.,

Yip, B., Nosyk, B., … Kendall, P. (2014). Expansion of HAART
coverage is associated with sustained decreases in HIV/AIDS
morbidity, mortality and HIV transmission: The “HIV Treatment
as Prevention” experience in a Canadian setting. PLoS ONE,
9(2), e87872. Retrieved from
https://doi.org/10.1371/journal.pone.0087872

• Roberts, H., & Hickey, M. (2016). Managing the menopause:
An update. Maturitas, 86(2016), 53–58.
https://doi.org/10.1016/j.maturitas.2016.01.007
• Agency for Healthcare Research and Quality. (2014). Guide to

clinical preventive services, 2014: Section 2.
Recommendations for adults. Retrieved from
http://www.ahrq.gov/professionals/clinicians-
providers/guidelines-recommendations/guide/section2.html
Media
• Laureate Education (Producer). (2019h). Pathopharmacology:

Pharmacology and immunological disorders: Improvements in
medications and drug administration [Video file]. Baltimore,
MD: Author.
• Speed Pharmacology. (2018). Pharmacology – Antibiotics –

Cell wall & membrane inhibitors (Made Easy) [Video].
https://www.youtube.com/watch?v=mMk6VWVpRpo&t=504s
• Speed Pharmacology. (2018). Pharmacology – Antibiotics –

DNA, RNA, folic acid, protein synthesis inhibitors (Made Easy)
[Video].
https://www.youtube.com/watch?v=5HQmvQJWzNY&t=32s
Discussion Women’s and Men’s Health, Infectious Disease, and Hematologic

Disorders
By Day 3 of Week 9
Post a brief description of your patient’s health needs from the

patient case study you selected. Be specific. Then, explain the type of
treatment regimen you would recommend for treating your patient,
including the choice or pharmacotherapeutics you would recommend
and explain why. Be sure to justify your response. Explain a patient
education strategy you might recommend for assisting your patient
with the management of their health needs. Be specific and provide
examples.
You will respond to your colleagues’ posts in Week 10.
Week 10 Women’s and Men’s Health/Infections and Hematologic

Systems, Part II

Resources Readings

372–388)
o Chapter 47, “Drugs for Deficiency Anemias” (pp. 389–396)
o Chapter 50, “Estrogens and Progestins: Basic
Pharmacology and Noncontraceptive Applications” (pp.
425–436)
o Chapter 51, “Birth Control” (pp. 437–446)
o Chapter 52, “Androgens” (pp. 447–453)
o Chapter 53, “Male Sexual Dysfunction and Benign Prostatic
Hyperplasia” (pp. 454–466)
o Chapter 70, “Basic Principles of Antimicrobial Therapy” (pp.
651–661)
o Chapter 71, “Drugs That Weaken the Bacterial Cell Wall I:
Penicillins” (pp. 662–668)
o Chapter 75, “Sulfonamides Antibiotics and Trimethoprim”
(pp. 688–694)
o Chapter 76, “Drug Therapy of Urinary Tract Infections” (pp.
695–699)
o Chapter 78, “Miscellaneous Antibacterial Drugs” (pp. 711–
714)
o Chapter 79, “Antifungal Agents” (pp. 715–722)
o Chapter 82, “Drug Therapy of Sexually Transmitted
Diseases” (pp. 763–770)
• Lunenfeld, B., Mskhalaya, G., Zitzmann, M., Arver, S.,

Kalinchenko, S., Tishova, Y., & Morgentaler, A. (2015).
Recommendations on the diagnosis, treatment and monitoring of
hypogonadism in men. Aging Male, 18(1), 5–15.
doi:10.3109/13685538.2015.1004049
• Montaner, J. S. G., Lima, V. D., Harrigan, P. R., Lourenço, L., Yip,

B., Nosyk, B., … Kendall, P. (2014). Expansion of HAART
coverage is associated with sustained decreases in HIV/AIDS
morbidity, mortality and HIV transmission: The “HIV Treatment as
Prevention” experience in a Canadian setting. PLoS ONE, 9(2),

e87872. Retrieved from
https://doi.org/10.1371/journal.pone.0087872
• Roberts, H., & Hickey, M. (2016). Managing the menopause: An

update. Maturitas, 86(2016), 53–58.
https://doi.org/10.1016/j.maturitas.2016.01.007
• Agency for Healthcare Research and Quality. (2014). Guide to

clinical preventive services, 2014: Section 2. Recommendations
for adults. Retrieved from
http://www.ahrq.gov/professionals/clinicians-providers/guidelines-
recommendations/guide/section2.html
• Document: Final Exam Study Guide (PDF)
Media
• Laureate Education (Producer). (2019h). Pathopharmacology:

Pharmacology and immunological disorders: Improvements in
medications and drug administration [Video file]. Baltimore, MD:
Author.
Discussion Women’s and Men’s Health, Infectious Disease, and Hematologic

Disorders
By Day 6 of Week 10
Read a selection of your colleagues’ responses from Week 9 and

respond to at least two of your colleagues on two different days
who selected a different patient case study, and provide
recommendations for alternative drug treatments to address the
patient’s pathophysiology. Be specific and provide examples.
Assignment Practicum Application Assignment
By Day 7
Submit either your Practicum Application or Practicum Plan

submission confirmation email PDF.

Module 8: Pediatrics
Week 11 Pediatrics
Resources Readings

o Chapter 9, “Drug Therapy in Pediatric Patients” (pp.
58—60)
• Corny, J., Lebel, D., Bailey, B., & Bussieres, J. (2015).

Unlicensed and off-label drug use in children before and after
pediatric governmental initiatives. The Journal of Pediatric
Pharmacology and Therapeutics, 20(4), 316–328. Retrieved
from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557722/
• Panther, S. G., Knotts, A. M., Odom-Maryon, T., Daratha, K.,

Woo, T., & Klein, T. A. (2017). Off-label prescribing trends for
ADHD medications in very young children. The Journal of
Pediatric Pharmacology and Therapeutics, 22(6), 423–429.
doi:10.5863/1551-6776-22.6.423
• Document: Final Exam Study Guide (PDF)
Media
• Laureate Education (Producer). (2019i). Therapy for pediatric

clients with mood disorders [Interactive media file]. Baltimore,
MD: Author.
Assignment Off-Label Drug Use in Pediatrics
By Day 7 of Week 11
Write a 1-page narrative in APA format that addresses the following:
• Explain the circumstances under which children should be

prescribed drugs for off-label use. Be specific and provide
examples.
• Describe strategies to make the off-label use and dosage of
drugs safer for children from infancy to adolescence. Include
descriptions and names of off-label drugs that require extra
care and attention when used in pediatrics.

Module 8: Pediatrics
Week 11 Pediatrics
Course Complete your Course Evaluation by Day 7.

Evaluation

USW1 NURS 6521 Courseschedule

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

USW1 NURS 6521 Courseschedule

Uploaded by

Copyright:

Available Formats

Course Schedule

NURS 6521: Advanced Pharmacology

Module 1: Foundational Concepts of Advanced Pharmacology

• Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s

• American Geriatrics Society 2019 Beers Criteria Update

• Drug Enforcement Administration. (n.d.-a). Code of federal

© 2021 Walden University, LLC Page 1 of 18

• Drug Enforcement Administration. (2006). Practitioner’s

• Drug Enforcement Administration. (n.d.-c). Registration.

• Fowler, M. D. M., & American Nurses Association. (2015).

• Institute for Safe Medication Practices. (2017). List of error-

• Ladd, E., & Hoyt, A. (2016). Shedding light on nurse

• Sabatino, J. A., Pruchnicki, M. C., Sevin, A. M., Barker, E.,

• Laureate Education (Producer). (2012). Introduction to

© 2021 Walden University, LLC Page 2 of 18

• Speed Pharmacology. (2015). Pharmacology –

• Speed Pharmacology. (2017). Pharmacology – Diuretics

• Speed Pharmacology. (2017). Pharmacology – Antiarrhythmic

• Speed Pharmacology. (2016). Pharmacology – Adrenergic

• Speed Pharmacology. (2017). Drugs for Hyperlipidemia (Made

Discussion Pharmacokinetics and Pharmacodynamics

Post a description of the case you were assigned. Then, describe

Read a selection of your colleagues’ responses and respond to at

© 2021 Walden University, LLC Page 3 of 18

Assignment 1 Course Acknowledgements

Assignment 2 Ethical and Legal Implications of Prescribing Drugs

Write a 2- to 3-page paper that addresses the following:

• Explain the ethical and legal implications of the scenario you

Module 2: Cardiovascular and Respiratory Systems

• Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s

© 2021 Walden University, LLC Page 4 of 18

• Laureate Education (Producer). (2009). Cardiovascular

• Walden University. (n.d.). Instructor feedback.

Assignment Pharmacotherapy for Cardiovascular Disorders

Write a 2- to 3-page paper that addresses the following:

• Explain how the factor you selected might influence the

• Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s

© 2021 Walden University, LLC Page 5 of 18

• Document: APA Presentation Template (PowerPoint

• Speed Pharmacology. (2020). Drugs for asthma and COPD

•Speed Pharmacology. (2017). Antihistamines (Made Easy)

Create a 5- to 6-slide PowerPoint presentation that can be used in a

• Describe long-term control and quick relief treatment options

Module 3: Gastrointestinal and Hepatobiliary Systems

• Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s

© 2021 Walden University, LLC Page 6 of 18

o Chapter 66, “Other Gastrointestinal Drugs” (pp. 605–

• Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi,

Assignment Pharmacotherapy for Gastrointestinal and Hepatobiliary

Write a 1-page paper that addresses the following:

• Explain your diagnosis for the patient, including your rationale

Module 4: Endocrine System

• Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s

© 2021 Walden University, LLC Page 7 of 18

• American Diabetes Association. (2018). Pharmacologic

• Document: Mid-Term Summary & Study Guide (PDF)

• Speed Pharmacology. (2017). Drugs for Diabetes (Made Easy)

Discussion Diabetes and Drug Treatments

Post a brief explanation of the differences between the types of

Read a selection of your colleagues’ responses and respond to at

Module 5: Neurologic and Musculoskeletal Systems and Opioids

© 2021 Walden University, LLC Page 8 of 18